Curriculum Vitae

Personal information Alfonso Galderisi

Work experience

Harvard Medical School (Boston, MA – USA)	Internship	09/2008	Pediatric Diabetology
Harvard Medical School (Boston, MA – USA)	Internship	09/2009	Pediatric Diabetology
Second University of Naples (Naples, Italy)	M.D.	07/2010	Medicine
University of Padova (Padova, Italy)	Residency/ Fellowship	07/2017	Pediatrics/ Neonatal Endocrinology
Harvard Medical School (Boston, MA – USA)	Research Fellowship	09/2016	Pediatric Diabetology
Yale University (New Haven, CT – USA)	Research Fellowship	02/2019	Pediatric Endocrinology
University of Padova (Padova, Italy)	Assistant Professor	2019-2022	Pediatric Endocrinology
Institute for Pediatric Research (Padova, Italy)	Researcher	2022-current	Pediatric Endocrinology
Yale University (New Haven, CT – USA)	Assistant Professor	2022-2025	Pediatric Endocrinology
	Associate Professor	01/2025-12/2025	Pediatric Endocrinology

Université Paris-Cité / APHP	Associate Professor [MCU-PH]	01/09/2025-	

Education and training

2008 Award For Excellent Students of the Second University of Naples
2008-2009 Award from the Exchange Student Program of the Second University of Naples (for a research project at Harvard Medical School, Joslin Diabetes Center, Boston, MA)
2010 Special Mention of the Faculty Dean for the degree thesis "Cardiac autoimmunity in pediatric T1D"
2010 Italian Medical Board Certification (code NA033175)
2012-2013 ECFMG – USMLE Step 1 and 2CK
2012 Match for the Pediatric Residency program of University of Padua (Italy) that was ranked 1st in Italy **2013** *Science School of* **ESPE** *(European Society for Pediatric Endocrinology)* 8-12 May, Haifa (Israel) **2013** *Early career grant of the Endocrine Society* **(ENDO 2013)**
2014 *Science School of the Italian Society of Pediatric Endocrinology and Diabetology* (**ISPED**, May-October 2014)
2014 ***Albert Renold Grant*** from the European Foundation for the Study of Diabetes (**EFSD-EASD**) for the research project: Cardiac Autoimmunity in Type 1 diabetes (Joslin Diabetes Center).
2015 *European Society of Pediatric Endocrinology (**ESPE**) Diabetes and Obesity School*, Lubjana (Slovenia), 16-18 April 2015
2015 ISPAD *(International Society for Pediatric and Adolescent Diabetes)* ***School****,* Milan – 19-24 April 2015
2016 ISPAD *(International Society for Pediatric and Adolescent Diabetes)* ***Research Fellowship Award*** *at Yale University (New Haven, CT)*
2017 Italian Pediatric Board Certification and Pediatric Endocrinology.
2017-2019 Patterson Trust Award Foundation Grant – ***Fellowship at Yale University (New Haven, CT)***
2025 – European Society for pediatric endocrinology (ESPE) – Young Investigator Award

2025 – American Diabetes Association (ADA) – Young Investigator Award

Additional information

Publications

Galderisi A, Bonet J, Ismail HM, Moran A, Fiorina P, Bosi E, Petrelli A. Metabolic phenotype of Stage 1 and Stage 2 type 1 diabetes using modelling of beta cell function. J Clin Endocrinol Metab. 2025 Feb 24:dgaf086. doi: 10.1210/clinem/dgaf086. Epub ahead of print. PMID: 39992257.
• Galderisi A, Sims EK, Evans-Molina C, Petrelli A, Cuthbertson D, Nathan BM, Ismail HM, Herold KC, Moran A. Trajectory of beta cell function and insulin clearance in stage 2 type 1 diabetes: natural history and response to teplizumab. Diabetologia. 2025 Mar;68(3):646-661. doi: 10.1007/s00125-024-06323-0. Epub 2024 Nov 19. PMID: 39560746; PMCID: PMC11832608.
• Martino M, Galderisi A, Evans-Molina C, Dayan C. Revisiting the Pattern of Loss of β-Cell Function in Preclinical Type 1 Diabetes. Diabetes. 2024 Nov 1;73(11):1769-1779. doi: 10.2337/db24-0163. PMID: 39106185.
• Galderisi A, Marks BE, DiMeglio LA, de Beaufort C. Endpoints for clinical trials in type 1 diabetes drug development. Lancet Diabetes Endocrinol. 2024 May;12(5):297-299. doi: 10.1016/S2213-8587(24)00097-4. PMID: 38663944; PMCID: PMC11230104.
• Galderisi A, Carr ALJ, Martino M, Taylor P, Senior P, Dayan C. Quantifying beta cell function in the preclinical stages of type 1 diabetes. Diabetologia. 2023 Dec;66(12):2189-2199. doi: 10.1007/s00125-023-06011-5. Epub 2023
Sep 15. Erratum in: Diabetologia. 2025 Feb;68(2):472-473. doi: 10.1007/s00125-024-06335-w. PMID: 37712956; PMCID: PMC10627950.
• Galderisi A, Tricò D, Lat J, Samuels S, Weiss R, Van Name M, Pierpont B, Santoro N, Caprio S. Incretin effect

determines glucose trajectory and insulin sensitivity in youths with obesity. JCI Insight. 2023 Nov 22;8(22):e165709. doi: 10.1172/jci.insight.165709. PMID: 37847560; PMCID: PMC10721315.
• Galderisi A, Moran A, Evans-Molina C, Martino M, Santoro N, Caprio S, Cobelli C. Early Impairment of Insulin Sensitivity, β-Cell Responsiveness, and Insulin Clearance in Youth with Stage 1 Type 1 Diabetes. J Clin Endocrinol Metab. 2021 Aug 18;106(9):2660-2669. doi: 10.1210/clinem/dgab344. PMID: 34000022; PMCID: PMC8372628.
• Galderisi A, Evans-Molina C, Martino M, Caprio S, Cobelli C, Moran A. β-Cell Function and Insulin Sensitivity in Youth With Early Type 1 Diabetes From a 2-Hour 7-Sample OGTT. J Clin Endocrinol Metab. 2023 May 17;108(6):1376-1386. doi: 10.1210/clinem/dgac740. Erratum in: J Clin Endocrinol Metab. 2023 Apr 25;: PMID: 36546354; PMCID: PMC10188312.
• Galderisi A, Polidori D, Weiss R, Giannini C, Pierpont B, Tricò D, Caprio S. Lower Insulin Clearance Parallels a Reduced Insulin Sensitivity in Obese Youths and Is Associated With a Decline in β-Cell Function Over Time. Diabetes. 2019 Nov;68(11):2074-2084. doi: 10.2337/db19-0120. Epub 2019 Aug 9. PMID: 31399433; PMCID: PMC6804624.
• Galderisi A, Giannini C, Weiss R, Kim G, Shabanova V, Santoro N, Pierpont B, Savoye M, Caprio S. Trajectories of changes in glucose tolerance in a multiethnic cohort of obese youths: an observational prospective analysis. Lancet Child Adolesc Health. 2018 Oct;2(10):726-735. doi: 10.1016/S2352-4642(18)30235-9. Epub 2018 Aug 24. PMID: 30236381; PMCID: PMC6190831.
C2.

Galderisi A, Facchinetti A, Steil GM, Ortiz-Rubio P, Cavallin F, Tamborlane WV, Baraldi E, Cobelli C, Trevisanuto D. Continuous glucose monitoring in very preterm infants: a randomized controlled trial. Pediatrics. 2017 Oct;140(4). PMID: 28916591
• Galderisi A, Zammataro L, Losiouk E, Lanzola G, Kraemer K, Facchinetti A, Galeazzo B, Favero V, Baraldi E, Cobelli C, Trevisanuto D, Steil GM. Continuous glucose monitoring Linked to an Artificial Intelligence Risk index (CLAIR): early footprints of IVH in preterm neonates. Diabetes Technol Ther., 2019; 21(3) DOI: 10.1089/dia.2018.0383
• Galderisi A, Lago P, Steil GM, Ghirardo M, Cobelli C, Baraldi E, Trevisanuto D Procedural Pain during Insertion of a Continuous Glucose Monitoring Device in Preterm Infants. J Pediatr. 2018 Sep;200:261-264.e1. doi: 10.1016/j.jpeds.2018.03.040. Epub 2018 May 31. PMID: 2986131
• Galderisi A, Brigadoi S, Cutini S, Moro SB, Lolli E, Meconi F, Benavides-Varela S, Baraldi E, Amodio P, Cobelli C, Trevisanuto D, Dell'Acqua R. Long-term continuous monitoring of the preterm brain with diffuse optical tomography and electroencephalography: a technical note on cap manufacturing. Neurophotonics. 2016 Oct;3(4):045009. doi: 10.1117/1.NPh.3.4.045009. PMID: 28042587
• Galderisi A, Res G, Guiducci S, Savio F, Brigadoi S, Forlani L, Mastrandrea B, Moschino L, Lolli E, Priante E, Trevisanuto D, Baraldi E. Glucose variability increases during minimally invasive procedures in very preterm infants. Eur J Pediatr. 2023 Jan;182(1):89-94. doi: 10.1007/s00431-022-04641-2. Epub 2022 Oct 6. PMID: 36201017; PMCID: PMC9829573.
• Galderisi A, Tordin M, Suppiej A, Cainelli E, Baraldi E, Trevisanuto D. Glucose-to-lactate ratio and neurodevelopment in infants with hypoxic-ischemic encephalopathy: an observational study. Eur J Pediatr. 2023 Feb;182(2):837-844. doi: 10.1007/s00431-022-04694-3. Epub 2022 Dec 9. PMID: 36484862; PMCID: PMC9899169.
• Guiducci S, Res G, Bonadies L, Savio F, Brigadoi S, Priante E, Trevisanuto D, Baraldi E, Galderisi A. Impact of macronutrients intake on glycemic homeostasis of preterm infants: evidence from continuous glucose monitoring. Eur J Pediatr. 2024 Apr 18. doi: 10.1007/s00431-024-05532-4. Epub ahead of print. PMID: 38637447.
• Bonet J, Guiducci S, Res G, Brigadoi S, Sen S, Montaldo P, Priante E, Santoro N, Trevisanuto D, Baraldi E, Dalla Man C, Galderisi A. Continuous Glucose Monitoring among Infants Born Very Preterm: Evidence for Accuracy in Neonatal Intensive Care. J Pediatr. 2025 Mar;278:114416. doi: 10.1016/j.jpeds.2024.114416. Epub 2024 Nov 22. PMID: 39579867.

Projects

1. Agency: Juvenile Diabetes Research Foundation/BreakthroughT1D - I.D.#: 3-SRA-2022-1186-S-B - Title: Phenotyping RElatives of persons with Diabetes with CGM and Tests of beta-cell function and health (PREDICT): an integrated longitudinal assessment of deep metabolic phenotyping and CGM metrics in youth at risk for T1D - Role:PI

2. Agency: Juvenile Diabetes Research Foundation/BreakthroughT1D - I.D.#: 3-SRA-2023-1422-S-B - Title: Tracking disease progression in early stage T1D using an automated version of the oral minimal model. Role : Co-PI

3. Agency: ENABLE Biosciences (LLC, UK)- I.D.#: 2000037027 - Title: Clinical validation of islet autoantibody measurement in self-collected dried blood spot specimens - Role : PI

4. Agency : BreakthroughT1D (formerly JDRF) - ID: 2-SRA-2024-1563-S-B - Title : Mechanistic Etiologies Underlying the Impact of Verapamil to Preserve β Cell Function in Type 1 diabetes. Role: Coinvestigator

5. Agency: NIH/NIDDK - I.D.#: 2000031181 (HIC) (ongoing clinical trial) - Title: Semaglutide, 2.4mg, once weekly: Effects on Beta-cell Preservation and Reduction of Intrahepatic Triglyceride Content in Obese Youth with Prediabetes (IGT)/New Onset Type 2 Diabetes (T2D) and Non-Alcoholic Fatty Liver Disease (NAFLD) - Role: Coinvestigator

6. Agency : Fondation Francophone pour la recherche en Diabetologie (FFRD) - Title : Verapamil in Preclinical Type 1 diabetes. Role : PI.

Memberships

Membership :

- International Society for pediatric and Adolescent Diabetes (ISPAD)
- European Society for Pediatric Endocrinology (ESPE)
- American Diabetes Association (ADA)

Awards :

- 2025 Young Investigator Award , European Society for Pediatric Endocrinology (ESPE)
- 2025 Diabetes In Youth Interest Group of the American Diabetes Association (ADA)

Invited Speaking Engagements, Presentations & Workshops:

- "New Technologies for glucose monitoring in preterm babies". University of Luxembourg, Centre Hospitalier de Luxembourg, Luxembourg, Luxembourg, Luxembourg, October 2019. (Lecture)
- "Glycemic control in preterm neonates". Brigham Women Hospital - Harvard Medical School, Brigham Women Hospital Grand Rounds, Grand Round Neonatal-Perinatal Medicine, December 2020. (Lecture)
- "The Padova Chart for Health in Children". University of Padova 800 Lecture, Padua, Veneto, Italy, April 2022. (Lecture)
- "A deeper look into diabetes “before” (T1)diabetes". University of Cardiff, Endocrinology Seminaries - Cardiff University, Cardiff, Wales, United Kingdom, July 2022. (Lecture)
- "New outcomes in type 1 diabetes". ESPE, European Society of Pediatric Endocrinology, Rome, Lazio, Italy, September 2022. (Lecture)
- "Big data and artificial intelligence in type 1 diabetes". ISPAD, International Society Pediatric and Adolescent Diabetes - 48th Annual Conference, Abu Dhabi, Abu Dhabi, United Arab Emirates, October 2022. (Lecture)

- "Beyond the glucose-centric diabetes management: The path to multiple sensing". ATTD, Advanced Technologies Treatments for Diabetes - 16th International Conference, Berlin, BE, Germany, February 2023. (Lecture)
- "The path to multiple metabolic sensing". National Institute of Health (NIH), Workshop on artificial pancreas, Bethesda, MD, May 2023. (Lecture)
- "Lifestyles and health promotion: the role of pediatricians", European Academy of Pediatrics, Padova, Italy, May 2023 (Lecture)
- "Diabetes Technologies with a Global Perspective", ADA, American Diabetes Association, San Diego, CA, June 2023 (Lecture)
- "Inhaled Insulin". Diabetes Technology Meeting, virtual meeting, November 2023. (Lecture)
- "Beta cell function in the early T1D stages". University of Paris, Seminaries of Pediatric Endocrinology, Paris, IDF, France, January 2024. (Lecture)
- "Transient and Persistent Neonatal Hyperglycemia : mechanisms and therapeutic options.". Pediatric Academic Societies Meeting (PAS), Toronto, ON, Canada, May 2024. (Lecture)
- "Endpoints for Type 1 Diabetes Prevention Trials" INNODIA Lectures Series (Lecture) July, 2024
- "Implications of using AI-CDSS in diabetes care" European Association for the Study of Diabetes (EASD), Madrid, Spain, September 2024 (Lecture)
- "The Physiopathology of Insulin Sensitivity & Secretion in the Early Stages of T1D"; 22nd World Congress in Insulin Resistance, Diabetes, and Cardiovascular Disease – 12-15 December 2024, Los Angeles, CA (Lecture)

Other Relevant Information